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Since 1988, TCC of PMIVSD became an alternative treatment for anatomically suitable
patients with high risk of surgical closure. TCC is less invasive but the optimal timing
and technique have not developed much in the last four decades. The dismal prognosis at
the contemporary sight should not be discouraged. The rapid innovation in TAVI is an
example. The learning curve slopes down to the line of inertia in inaction. Some innovations
have slept for centuries but their potential needs to be celebrated. The published experience
of TCC of PMIVSD across the globe is limited as they are based on consensus. The experience
related to clinical practice has heterogeneous topography around the globe because of the
morbid pathology. The increasing number of onsite cardiothoracic wings, better imaging
tools, LVADS, and ECMO, along with improvement in well matching hardware to the
pathology of PMIVSD, build incremental conﬁdence. The improved outcomes believes in
the enthusiasm of closing the PMIVSD using either surgical or TCC approach and is
recommended.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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journal homepage: www.elsevier.com/locate/ihjThere is phenomenal reduction in the incidence of mortality
due to coronary artery disease from 1960 to 2015, which is
reﬂected as lower incidence (0.2%) of PMIVSD. The mortality
rate is more than 90% at the end of the ﬁrst 2 months with
current medical management. The natural history shows
bimodal peak of occurrence of PMIVSD. The ﬁrst and second
peaks happen in 16–24 h and in 3 and 5 days after MI,
respectively. The limited time interval between the detection
of PMIVSD with cardiogenic shock and death is really a
challenge to manage in the different hospital settings. The
surgically treated patients suffer a mortality between 20% and
60%.1 The pre-operative hemodynamic stability improves
mortality rate but guideline opposes this waiting. The
operative mortality rate was 54% when the surgery was doneE-mail address: cardioramachandra@gmail.com.
http://dx.doi.org/10.1016/j.ihj.2015.06.038
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierwithin 7 days and it reduced to 18% when the surgery was done
after 7 days.1 The mortality was quite high when the surgery
was done in an emergency basis, especially within 6 h of MI.
The incidence of residual defect after surgical repair of post-MI
VSR was noted to be around 10–40%.2 The TCC of PMIVSD is
very useful when done after a an interval of primary PCI, after
2–3 weeks of MI, residual leak closure after surgery, and as a
bail out or salvage where surgical closure weighs more risk
than beneﬁt.3,4 The residual shunting, ventricular rupture,
device embolization, and adverse events experience during
follow-up in some patients are seen in 41% of patients when
TCC is done in acute (<2 weeks) and subacute (2–4 weeks)
conditions.4,5 The contraindications for transcatheter therapy
include defect size >35 mm, basal VSR near mitral or aortic B.V. All rights reserved.
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earlier revascularisation (primary PTCA or delayed PTCA) does
reduce incidence of VSR and size of VSR, and restores
hemodynamic stability, good for either surgical or device
closure. Because of the serpiginous border, a signiﬁcant number
of VSR failed to qualify for device closure. The heterogeneity in
the incidence of mortality with surgical or TCC in acute or
subacute cases is explained by timing of surgery for VSR,
cardiogenic shock, and recurrence of VSR, posterior VSR, and
inferior MI complicated with mitral regurgitation and renal
failure. In the current scenario, the mortality is quite high in
either surgical or TCC when performed in the ﬁrst 2–3 weeks.6
Because most of the deaths occur during in the ﬁrst 2 months
without intervention, American College of Cardiology and
American Heart Association recommend immediate surgical
repair, irrespective of shunt size. Of note is that transcatheter
closure of PMIVSR is off label.
The ﬁrst report of PMIVSR dates back to Latham's ﬁrst
description of PMIVSR at autopsy in 1847. In the year 1923,
Brunn made ﬁrst ante-mortem diagnosis of PMIVSR. In the
year 1934, Sager established speciﬁc clinical criteria for
diagnosis, stressing the association of PMIVSR with coronary
artery disease. In an article in 1957, Cooley et al. performed ﬁrst
surgical repair of PMIVSR. In 1988, Lock et al. reported ﬁrst the
transcatheter closure of VSR using cardioseal device, based on
their large experience of TCC of congenital VSD, and since then
approximately 300 cases of TCC have been reported worldwide
in the form of case reports, and small series with success rate
of approximately 80–90%.3 The periprocedural use of hemo-
dynamic support like IABP, ECMO, and Impela device provides
stability but the delay in intervention is supported by
consensus. There are several innovations that have been
introduced in this arena and are in pipeline. In the article in
2015, Zhou et al.7 reported the use of parachute device in case
of PMIVSD with left ventricular aneurysm. Cinq-Mars et al.8 in
an article titled ‘‘The novel use of heart transplantation for the
management of a case with multiple complications following
acute myocardial infarction’’, ﬁrst described the role of heart
transplantation to salvage a patient of PMIVSR. Ari et al.9
reported in 2012 percutaneous Closure of PMIVSR in a patient
with left ventricular apical thrombus, as a ﬁrst published
report. The choice of occluder is no more restricted to
dedicated PMIVSD occluder because of varying anatomy and
difference of time intervention from operator to operator.10
The waist size of PMIVSD occluder should comparatively be
larger by 6–8 cm when the size of VSD is compared, because of
their soft and friable border. The exact three-dimensional size
and shape should be well perceived before intervention. The
basic imaging tools are 2D and 3D echocardiography for
diagnosis and intervention. In the cases of complicated
anatomy, cardiac MRI would be complimentary or can replace
left ventricular angiogram in this aspect. Transjugular
approach is preferred to transfemoral approach. Balloon
dilatation is usually discouraged in acute or subacute setting
to assess the size of VSD. Risk stratiﬁcation can be supported
by EURO score. The contrast-induced nephropathy and device
embolization following it should not be ignored in the acute
and subacute setting because the intervention in these cases is
all about hemodynamically unstable patients and friable
border of PMIVSD. The meta-analysis reported by De Puyet al.3 shows the procedural success rate of 80–90% with TCC.
There are two case reports and one small series has been
reported from India.10–12Though there is drastic reduction in
the incidence of PMIVSR with improvement in pharmaco-
invasive therapy from 3% to 0.17% in APEX-MI registry,13 this
should neither encourage cardiologists to sit cross legged nor
be completely biased by AHA/ACC decision saying that surgery
is indicated in this condition irrespective of clinico-hemody-
namic aspect. A scientist makes science and not the reverse.
The device closure of PMIVSD is currently the second choice
and is in the upslope of the learning curve. Indian researchers
should take more initiative in this regard to add to the
experience of transcatheter closure of PMIVSR using hemody-
namic supportive measures like ECMO, Impella and IABP to
improve periprocedural results. The results with surgical
closure are closely similar to TCC. Therefore, TCC should be
encouraged whenever hemodynamic condition and morphol-
ogy are suitable to device closure. The coronary artery disease
burden and certainly its related complication would arise in
the coming days in India. Therefore, the cardiologist, as
evidenced, should show interest in TCC as a viable alternative.
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